SCHEMBL30260628

SCHEMBL30260628

O=C(N=Nc1c(O)[nH]c2ccccc12)Nc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.74
MGLL Q99685 1/20 0.74
KDR P35968 4/20 0.70
GSK3B P49841 1/20 0.61
MAPT P10636 7/20 0.61
KMT2A Q03164 4/20 0.61
TDP1 Q9NUW8 3/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
MEN1 O00255 3/20 0.61
LMNA P02545 3/20 0.61
GAA P10253 2/20 0.61
HCRTR1 O43613 1/20 0.61
UBE2N P61088 1/20 0.61
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA9 Q16790 2/20 0.61
MET P08581 1/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
HTT P42858 2/20 0.58
RAB9A P51151 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23483662 1.00 FAAH (0.74) FAAHMGLLKDRGSK3BMAPT
SCHEMBL30260537 0.83 MAPT (0.85) KDRMAPTKMT2ATDP1L3MBTL1
SCHEMBL30260468 0.78 MAPT (0.72) GSK3BMAPTKMT2ATDP1L3MBTL1
SCHEMBL23483889 0.78 MAPT (0.72) GSK3BMAPTKMT2ATDP1L3MBTL1
SCHEMBL23483675 0.75 MET (1.00) MAPTLMNAMETRAB9AALDH1A1
SCHEMBL30260452 0.75 MET (1.00) MAPTLMNAMETRAB9AALDH1A1
SCHEMBL23483661 0.74 RAB9A (0.72) GSK3BMAPTKMT2ATDP1L3MBTL1
SCHEMBL30260571 0.74 RAB9A (0.72) GSK3BMAPTKMT2ATDP1L3MBTL1
SCHEMBL30260471 0.74 MAPT (0.67) GSK3BMAPTKMT2ATDP1L3MBTL1
SCHEMBL23483898 0.72 KMT2A (1.00) MAPTKMT2AL3MBTL1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER THE TRUSTEES OF DARTMOUTH COLLEGE 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER MYCBP, MYC, TERF2IP FAAH 4719/4885MGLL 4110/4885KDR 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.